180 related articles for article (PubMed ID: 8957064)
1. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas.
Imai Y; Oda H; Arai M; Shimizu S; Nakatsuru Y; Inoue T; Ishikawa T
Jpn J Cancer Res; 1996 Oct; 87(10):1056-62. PubMed ID: 8957064
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand.
Kiba T; Tsuda H; Pairojkul C; Inoue S; Sugimura T; Hirohashi S
Mol Carcinog; 1993; 8(4):312-8. PubMed ID: 8280380
[TBL] [Abstract][Full Text] [Related]
3. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
[TBL] [Abstract][Full Text] [Related]
4. [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers].
Pozharisskiĭ KM; Granov DA; Ten VP; Kubaĭbergenova AG; Leenman EE; Rasskazov AI
Vopr Onkol; 2008; 54(4):417-33. PubMed ID: 18942395
[TBL] [Abstract][Full Text] [Related]
5. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas.
Murakami Y; Hayashi K; Hirohashi S; Sekiya T
Cancer Res; 1991 Oct; 51(20):5520-5. PubMed ID: 1655254
[TBL] [Abstract][Full Text] [Related]
6. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma.
Haratake J; Hashimoto H
Liver; 1995 Feb; 15(1):9-15. PubMed ID: 7539881
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.
Goodman ZD; Ishak KG; Langloss JM; Sesterhenn IA; Rabin L
Cancer; 1985 Jan; 55(1):124-35. PubMed ID: 2578078
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of hepatocellular and cholangiocellular carcinoma in different hepatic lobes.
Ito Y; Fujioka H; Matsuzaki S; Yamamoto O; Okudaira S; Azuma T; Furui J; Kanematsu T
Hepatogastroenterology; 2003; 50(49):65-8. PubMed ID: 12629992
[TBL] [Abstract][Full Text] [Related]
10. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.
Sciarra A; Park YN; Sempoux C
Hum Pathol; 2020 Feb; 96():48-55. PubMed ID: 31931021
[TBL] [Abstract][Full Text] [Related]
11. Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.
Kashii T; Mizushima Y; Monno S; Nakagawa K; Kobayashi M
J Cancer Res Clin Oncol; 1994; 120(3):143-8. PubMed ID: 8263009
[TBL] [Abstract][Full Text] [Related]
12. Genetic classification of combined hepatocellular-cholangiocarcinoma.
Fujii H; Zhu XG; Matsumoto T; Inagaki M; Tokusashi Y; Miyokawa N; Fukusato T; Uekusa T; Takagaki T; Kadowaki N; Shirai T
Hum Pathol; 2000 Sep; 31(9):1011-7. PubMed ID: 11014564
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of canine primary liver carcinomas: distribution of alpha-fetoprotein, carcinoembryonic antigen, keratins and vimentin.
Martín de las Mulas J; Gómez-Villamandos JC; Pérez J; Mozos E; Estrado M; Méndez A
Res Vet Sci; 1995 Sep; 59(2):124-7. PubMed ID: 8525100
[TBL] [Abstract][Full Text] [Related]
14. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China.
Fujimoto Y; Hampton LL; Wirth PJ; Wang NJ; Xie JP; Thorgeirsson SS
Cancer Res; 1994 Jan; 54(1):281-5. PubMed ID: 7903205
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
16. Somatic changes in primary liver cancer in Russia: a pilot study.
Kalinina O; Marchio A; Urbanskii AI; Tarkova AB; Rebbani K; Granov DA; Dejean A; Generalov MI; Pineau P
Mutat Res; 2013 Aug; 755(2):90-9. PubMed ID: 23830926
[TBL] [Abstract][Full Text] [Related]
17. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
Sasaki M; Nakanuma Y; Ho SB; Kim YS
Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
Cazals-Hatem D; Rebouissou S; Bioulac-Sage P; Bluteau O; Blanché H; Franco D; Monges G; Belghiti J; Sa Cunha A; Laurent-Puig P; Degott C; Zucman-Rossi J
J Hepatol; 2004 Aug; 41(2):292-8. PubMed ID: 15288479
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
Tannapfel A; Sommerer F; Benicke M; Katalinic A; Uhlmann D; Witzigmann H; Hauss J; Wittekind C
Gut; 2003 May; 52(5):706-12. PubMed ID: 12692057
[TBL] [Abstract][Full Text] [Related]
20. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study.
Tickoo SK; Zee SY; Obiekwe S; Xiao H; Koea J; Robiou C; Blumgart LH; Jarnagin W; Ladanyi M; Klimstra DS
Am J Surg Pathol; 2002 Aug; 26(8):989-97. PubMed ID: 12170085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
